Relationship of Plasma HIV-1 RNA Dynamics to Baseline Factors and Virological Responses to Highly Active Antiretroviral Therapy in Adolescents (Aged 12-22 Years) Infected through High-Risk Behavior

Journal of Infectious Diseases

Volumn 189, Issue 4, 2004, Pages 593-601

  Wu, Hulin ^a,c   Lathey, Janet ^b   Ruan, Ping ^c   Douglas, Steven D ^d   Spector, Stephen A ^b   Lindsey, Jane ^c   Hughes, Michael D ^c   Rudy, Bret J ^d   Flynn, Patricia M ^e  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REDUCTION; SCHOOL CHILD; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HIV-1; HUMANS; MALE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK-TAKING; RNA, VIRAL; TIME FACTORS; UNITED STATES; VIRAL LOAD;

EID: 1442325333     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381500     Document Type: Article

References (25)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
2. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
5. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints. J Infect Dis 1999; 179:799-807.
6. Luzuriaga K, Wu H, McManus M, et al. Dynamics of HIV-1 replication in vertically infected infants. J Virol 1999; 73:362-7.
7. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 1999; 41:3-44.
8. Ding AA, Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math Biosci 1999; 160:63-82.
9. Wu H, Ding A, DeGruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS 1999; 13:429-30.
10. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998; 12:1483-90.
11. Mueller BU, Zeichner SL, Kuznetsov VA, Heath-Chiozzi M, Pizzo PA, Dimitrov DS. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 1998; 12:F191-6.
12. Wu H, Wu L. Identification of significant host factors for HIV dynamics modeled by nonlinear mixed-effect models. Stat Med 2002; 21:753-71.
13. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45: 1438-43.
14. Huang W, De Gruttola V, Fischl M, et al. Pattern of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis 2001; 183:1455-65.
15. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantitative methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994; 170:553-62.
16. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus 1 RNA in plasma by the AIDS clinical trials group virology laboratories. J Clin Microbiol 1996; 34:2695-701.
17. Douglas SD, Rudy B, Muenz L, et al. Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. AIDS 1999; 13:1629-15.
18. Wu H, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999; 55:410-8.
19. Ding AA, Wu H. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics 2000; 56:293-300.
20. Ding AA, Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2001; 2:13-29.
21. Robbins G, DeGruttola V, Shafer R, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
22. Spector SA, Hsia K, Yong FH, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis 2000; 182:1769-73.
23. Wu H, Mellors J, Ruan P, et al. Viral dynamics and their relations to baseline factors and long-term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J Acquir Immune Defic Syndr 2003; 32:557-64.
24. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-5.
25. Wu H, Ding AA. Design of viral dynamic studies for efficiently assessing anti-HIV therapies in AIDS clinical trials. Biom J 2002; 2:175-96.